A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH
Status:
Completed
Trial end date:
2018-10-22
Target enrollment:
Participant gender:
Summary
This study will be the initial exploration of pegcetacoplan in patients with PNH. The
assessments of the safety, tolerability, PK, and PD following administration of single and
multiples doses of pegcetacoplan will guide decisions to further develop the drug.